Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.

Stravokefalou, Vasiliki; Stellas, Dimitris; Karaliota, Sevasti; Nagy, Bethany A; Valentin, Antonio; Bergamaschi, Cristina; Dimas, Konstantinos; Pavlakis, George N

Stravokefalou, Vasiliki; Stellas, Dimitris; Karaliota, Sevasti; Nagy, Bethany A; Valentin, Antonio; Bergamaschi, Cristina; Dimas, Konstantinos; Pavlakis, George N.

Afiliação

Stravokefalou V; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, United States.
Stellas D; Department of Pharmacology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Karaliota S; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, United States.
Nagy BA; Department of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Valentin A; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, United States.
Bergamaschi C; Basic Science Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, United States.
Dimas K; Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, United States.
Pavlakis GN; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, United States.

Front Immunol ; 13: 1014802, 2022.

Article em En | MEDLINE | ID: mdl-36713398

Assuntos

Antineoplásicos; Células Neoplásicas Circulantes; Neoplasias de Mama Triplo Negativas; Humanos; Animais; Camundongos; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Interleucina-15/uso terapêutico; Linhagem Celular Tumoral; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Doxorrubicina/uso terapêutico; Fatores Imunológicos/uso terapêutico

Palavras-chave

chemoimmunotherapy; circulating tumor cells (CTCs); doxorubicin; heterodimeric IL-15 (hetIL-15); metastasis; surgery; triple negative breast cancer (TNBC)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Células Neoplásicas Circulantes / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google